Estrella Immunopharma Inc. (ESLA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.52 (-0.48%), Market cap $0.05B, 52-week low–high $0.82 ~ $3.05.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eur
Financial statements, price targets, institutional (13F) holdings and related news for Estrella Immunopharma Inc. are updated in real time on BlackAll Trade.
Estrella Immunopharma Inc. trades at $0.52 (-0.48%). Real-time quotes and charts are available on BlackAll Trade.
Estrella Immunopharma Inc. has a market cap of about $0.05B.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB10